- This topic has 3 replies, 3 voices, and was last updated 5 years ago by .
Viewing 4 posts - 1 through 4 (of 4 total)
Viewing 4 posts - 1 through 4 (of 4 total)
- You must be logged in to reply to this topic.
Interactive BPP books for September 2026 exams, recommended by OpenTuition.
Get discount code >>
Forums › Ask ACCA Tutor Forums › Ask the Tutor ACCA AFM Exams › CIGNO SEP/DEC 15
Hi John
Can you please help with this query?
The value of Cigno after the acquisition of Anatra becomes $128m
(This is before the potential tax and redundancy savings).
However, I must be missing something as I know that:
Value of Unbundling the manufacturing is $5,594, and
Value of Anatra is $31,884
So how is the $128 been derived?
Thank you.
The total value of Anantra following the unbundling of manufacturing and absorbing medical R&D is $37,478 (5,594 + 31,884)
The total value attributable to Anatra’s investors is $37,350 (21,000 + 9,000 + 7,350 (premium))
Therefore the value attributable to Cigno’s shareholders is 37,478 – 37,350 = $128.
Hi John
A small question on the above.
Why is it that the $128m is attributable to shareholders?
As the company’s capital split post acquisition is debt to equity 40:60 surely only 60% of the $128m is attributable to the shareholders and the remainder to debt holders.
Thanks in advance
Any gains due to synergy etc. only ever go to equity, never to debt.
The ratio of debt to equity is needed in order to calculate the cost of capital – how they manage to achieve that ratio is not relevant.
